Third-Party Lab Verified
HPLC + MS
HPLC + MS
Independently tested for identity and purity
Batch
NP-PT141-062426-01
NP-PT141-062426-01
Tested
Jul 28, 2026
Jul 28, 2026
Purity
99.72%
99.72%
View Certificate of Analysis
PT-141
|
Bremelanotide — Cyclic Melanocortin Peptide
|
Bremelanotide — Cyclic Melanocortin Peptide
Receptor Target
MC4R
Research Pathway
Melanocortin
Scaffold
7 AA Cyclic Lactam
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH), structurally derived from the Melanotan-II scaffold via removal of the C-terminal amide and formation of a lactam bridge between Asp&sup5; and Lys¹⁰. It exhibits potent, non-selective agonist activity at melanocortin receptor subtypes — with highest affinity at MC4R — and has been extensively studied in preclinical models investigating the central melanocortin system. Its cyclic architecture confers enhanced metabolic stability relative to linear α-MSH analogues. Supplied by NexPept as lyophilized powder for in vitro laboratory research use.
Molecular Profile
| Property | Detail |
|---|---|
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Residue Count | 7 AA (cyclic heptapeptide) |
| Cyclic Bridge | Lactam — Asp&sup5; side-chain to Lys¹⁰ ε-amine |
| Key Substitutions | Nle⁴ (norleucine for Met); D-Phe⁷ (receptor pharmacophore) |
| Molecular Formula | C₅₀H₆₈N₁₄O₁₀ |
| Molecular Weight | ~1025.2 Da |
| CAS Number | 189691-06-3 |
| Also Known As | Bremelanotide; PT141 |
| Parent Scaffold | α-MSH / Melanotan-II analogue |
| Format | Lyophilized Powder — 10 mg/vial |
| Analytical Method | High-Performance Liquid Chromatography (HPLC) + Mass Spectrometry (MS) |
| Appearance | White to off-white lyophilized powder |
Research Targets & Receptor Profile
MC4R / Melanocortin 4
Primary high-affinity target; Gαs-coupled Class A GPCR expressed in hypothalamic nuclei. Central to melanocortin system research models.
MC1R / MC3R
Non-selective agonist activity across MC1R (pigmentation) and MC3R (energy homeostasis) receptor subtypes investigated in parallel research models.
cAMP / Gs Pathway
Receptor activation coupled to adenylyl cyclase via Gαs, elevating intracellular cAMP. Used as a downstream readout in melanocortin receptor binding assays.
Cyclic Lactam Scaffold: The intramolecular Asp&sup5;–Lys¹⁰ lactam bridge constrains the peptide backbone into a bioactive conformation that mimics the receptor-binding β-turn of α-MSH. D-Phe⁷ substitution is critical for MC4R selectivity and potency relative to the native linear sequence. PT-141 differs from Melanotan-2 only at the C-terminus — a free acid in place of the amide — which is covered in the PT-141 research guide.
Research Context
- →Derived from the Melanotan-II scaffold; the cyclic lactam design was developed to improve metabolic stability and receptor subtype selectivity compared to MT-II
- →Investigated in central melanocortin system research; MC4R is expressed in the paraventricular nucleus, arcuate nucleus, and other hypothalamic regions studied in neuroendocrine models
- →Used in preclinical melanocortin pharmacology studies as a reference MC4R agonist alongside SHU 9119 (antagonist) for receptor characterisation
- →The Nle⁴ substitution replaces oxidation-prone Met in native α-MSH, improving chemical stability in aqueous research buffers
- →Studied in rodent and primate models examining central vs. peripheral melanocortin receptor distribution and signalling dynamics
Storage & Handling
Store sealed lyophilized material under controlled laboratory conditions in accordance with validated institutional SOPs and applicable technical documentation. Protect from light and moisture.
- →Keep in original sealed vial until use in research protocols
- →The cyclic lactam bridge confers improved hydrolytic stability; handle reconstituted solutions under sterile conditions per institutional guidelines
- →Handle in accordance with institutional biosafety and chemical handling guidelines
Note: No preparation, reconstitution, or administration instructions are provided. This compound is supplied for in vitro laboratory research use only. All handling must be conducted by qualified personnel following institutional safety protocols.
Literature & Resources
- →PT-141 (Bremelanotide): Research Peptide Guide for Canada — NexPept overview: structure, receptor profile, PT-141 vs Melanotan-2, purity and storage
- →Melanotan 1 vs Melanotan 2 — context on the linear and cyclic branches of the α-MSH analogue family
- →Molinoff PB et al. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Ann N Y Acad Sci, 2003 — PMID 14668376
- →Rosen RC et al. “Bremelanotide: a review of clinical studies in hypoactive sexual desire disorder.” J Sex Med, 2014 — PMID 24916834
- →PubChem Compound — Bremelanotide (CID 9941444): pubchem.ncbi.nlm.nih.gov
- →PubMed — Bremelanotide — peer-reviewed scientific literature
Research Use Only. PT-141 / Bremelanotide (CAS 189691-06-3) is supplied exclusively for qualified laboratory and scientific research purposes. This product is not approved for human or veterinary use, is not a drug or supplement, and has not been evaluated by Health Canada, the FDA, or any regulatory authority for safety or efficacy in any application. No claims are made regarding therapeutic, diagnostic, or preventive properties. Researchers are responsible for ensuring all use complies with applicable institutional, regional, and federal regulations.
Be the first to review “PT-141 10MG”
Related products
Reviews
There are no reviews yet.